The most popular plan in the range More than 10,000 patients No insurance required

Tirzepatide is the active ingredient in Zepbound® and Mounjaro®, both made by Eli Lilly. There is no generic, and there will not be one for years. That single fact explains the spread in what you are quoted for the same molecule in the same month.

What you pay depends on which route you buy through, whether you have coverage, what dose you are on, and what is bundled in besides the drug. This page sets out every route with approximate figures as of September 2026, compares providers side by side including us, and shows where the costs hide. Society does not offer Zepbound, and this page tells you where to get it instead.

One thing to be clear about before you read further: Society does not offer Zepbound. Zepbound is on this page because it is the brand most people are comparing against, and you deserve its real price. If you want brand Zepbound, the routes above are yours to use and none of them run through us. What Society offers on the tirzepatide side is personalized compounded tirzepatide from $249 per month where a clinician determines it is appropriate, and brand Mounjaro from $1,395 per month for its approved type 2 diabetes use.

Two rows above are for a medication approved for type 2 diabetes and two are for a medication approved for chronic weight management. That distinction decides what you can be prescribed, and it is not a pricing question.

Compiled from publicly listed pricing and approximate as of September 2026. Prices in this category move monthly, so check each provider's own page before you rely on a number. Society is in the table on the same terms as everyone else, and where a competitor is cheaper, the table says so. Every figure here, ours included, is a published starting price.

Society is not the cheapest headline number in that table, and we are not going to pretend otherwise.

LillyDirect self-pay vials are cheaper than us for brand tirzepatide, and if you have a prescription and are comfortable managing your own care, that is a genuinely good deal. Membership-only providers advertise lower entry prices than our starting price. Several compounding-led providers run promotional first-month rates below $249. And we do not offer Zepbound at all, so if brand Zepbound is what you want, we are not the answer.

Our tirzepatide plans start at $249 per month. That is a starting price, not a ceiling and not a flat rate, and the price you are quoted depends on the plan a clinician determines is appropriate for you. A plan covers a personalized treatment plan, your medication, labs, tailored compounded medication where it is clinically appropriate, expedited shipping and continuous clinical assistance. You see your own price before you are asked to pay anything, because the evaluation takes about two minutes and costs nothing.

If you are optimizing for the cheapest possible first month, a promotional rate elsewhere will beat us. If you are optimizing for the cheapest honest twelve months, compare what each price actually covers rather than the headlines, and ask every provider for the number attached to the plan you would really be placed on.

Tirzepatide is under patent, so no generic manufacturer can make it and no price competition exists. The list price, roughly $1,086 per month as of September 2026, is the same across every strength from 2.5mg to 15mg. What changes your cost is the channel.

Insurance. If your plan covers Zepbound for weight management you pay a copay, often $25 to $100. Coverage is not the default, and many employer plans exclude weight management medication entirely. See our guide to what insurance covers.

Manufacturer self-pay. Eli Lilly sells single-dose vials directly to people paying cash through LillyDirect, in the region of $349 for the 2.5mg starting strength and $499 for higher strengths as of September 2026. Check LillyDirect for the figure on the day, because it has changed repeatedly. You still need a valid prescription, the vials are drawn with a separate syringe rather than delivered by a pen, and self-pay pricing generally cannot be combined with an insurance claim.

Savings cards. With commercial insurance that does not cover Zepbound, the Eli Lilly savings card reduced the cost to around $650 per month as of September 2026. Medicare, Medicaid and other government insurance are excluded from manufacturer savings cards by federal rules.

Retail cash. Walking in with a prescription and no program gets you list price. There is rarely a reason to do this.

Telehealth. A provider bundles the prescriber visit with a medication supply at one price. Compare that against a pharmacy price plus a separate office visit, not against a pharmacy price alone.

A compounded preparation is made by a pharmacy for one named patient, on the direction of that patient's prescriber. It is not a generic, it is not a cheaper version of a brand, and it is not something you choose from a menu. It exists because a clinician has documented that the commercially available product does not meet a particular patient's clinical needs, for instance a documented allergy to an excipient in the approved product or a strength that is not commercially available.

The regulatory position narrowed sharply in 2025, so if you researched this market in 2024 the version you remember no longer exists. Compounding a product that is essentially a copy of a commercially available drug has not been permitted for 503A pharmacies or 503B outsourcing facilities since mid-2025. On 30 April 2026, FDA proposed permanently excluding semaglutide, tirzepatide and liraglutide from the 503B bulk drug substances list. What remains is the narrow, patient-specific 503A route described above.

Society's compounded tirzepatide plans start at $249 per month, available only where a Society clinician determines that a commercially available product does not meet your clinical needs. Compounded medications are not FDA-approved and have not been evaluated by the Food and Drug Administration for safety, efficacy or quality. A compounded preparation is not a generic and is not equivalent to Zepbound or Mounjaro.

Six questions to ask before you believe a low number, ours included.

1. Is medication in the price, or is this a membership? A fee that buys access to a prescriber is not a medication price.

2. Is that a starting price or the whole price? Most published prices in this category are starting prices, ours included. Ask what the plan you would actually be put on costs before you compare anything.

3. Is it a first-month promotional rate? Ask what month two costs, and month six.

4. Does it require annual prepay? If you stop, including for side effects you cannot tolerate, ask the refund policy before you pay.

5. Are consultations, labs, dose changes and shipping extra? Four separate $25 charges is $100 a month that was not in the headline.

6. What are the refund terms, not just the cancellation terms? Those are different questions. Ours: you can pause, switch or cancel anytime, cancelling stops future billing cycles only, the first two months of any treatment plan are non-refundable, and refund requests must be submitted within 28 days of the charge. Ask any provider for both halves of that answer in writing.

Run any offer through those six and compare twelve-month totals. The ranking usually changes.

Check your formulary before assuming you are not covered. Call member services and ask whether Zepbound is on formulary and what the prior authorization criteria are. Our guide to GLP-1 insurance coverage has the exact questions.

If your plan covers it, use the savings card on top. A covered claim plus a card is the cheapest outcome for most commercially insured patients.

If your plan excludes it, price LillyDirect first. For brand tirzepatide this is usually the lowest genuine cost.

Ask what the plan costs, not what it starts at. Published prices across this market are starting prices, ours included, so get the figure for the plan you would actually be on before you compare providers.

Use pre-tax dollars. GLP-1 medication for a diagnosed condition is generally HSA and FSA eligible, often with a letter of medical necessity. That is an effective discount equal to your marginal tax rate.

Ask whether a lower-cost medication is clinically appropriate. Metformin, from $99 per month at Society, is a different medication with different expected effects, appropriate for some patients and not others. That is a clinical conversation, not a price substitution.

See our transparent pricing page for everything we offer, or our guide to getting a GLP-1 without insurance if you have no coverage at all. Semaglutide is generally the cheaper molecule: our compounded semaglutide plans start at $149 per month against $249 for tirzepatide, and the two differ in mechanism, dosing and side effect profile, so cost is one input rather than the decision.

Tirzepatide plans start at $249 per month and semaglutide plans at $149. The evaluation costs nothing, you can pause, switch or cancel anytime, which stops future billing cycles, and the first two months of any treatment plan are non-refundable.

* Individual results may vary, and not all patients will qualify for treatment. Always consult a licensed healthcare provider before starting or modifying any medical treatment.

Society facilitates access to consultations with independent, licensed healthcare providers who evaluate each patient and determine eligibility for treatment. Prescription products require an online medical evaluation. Medications are prescribed by independent physicians and dispensed by licensed U.S. pharmacies or a patient's preferred pharmacy. Only a qualified healthcare provider can determine whether a treatment is appropriate for an individual's specific medical needs.
Providers are licensed in the state where the patient is located at the time of consultation, and availability may vary by state.
Society's services are intended for individuals 18 years of age or older. Age verification may be required as part of the intake process.
‍Society partners with licensed U.S. pharmacies. Certain treatments may include compounded medications, which are not FDA-approved and have not been evaluated by the Food and Drug Administration for safety, efficacy, or quality. Compounded medications may be prescribed by a healthcare provider based on individual patient needs or during periods of drug shortages. FDA-approved GLP-1 medications—such as Ozempic® (semaglutide), Wegovy® (semaglutide), and Zepbound® (tirzepatide)—are not compounded. Society is not affiliated with, endorsed by, or sponsored by the manufacturers of these products. All trademarks and brand names belong to their respective owners.
GLP-1–based treatments may carry risks, including the potential for thyroid C-cell tumors. These medications should not be used by individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Please consult a healthcare provider for complete prescribing and safety information.
Prescription medications are dispensed only when determined appropriate by a licensed healthcare provider following an online medical evaluation. No prescription is guaranteed, and treatment decisions are made solely at the prescriber's clinical discretion.
Statements on this website have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Images shown are for illustrative purposes only; actual product appearance may vary.